Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The vials were emptied and ~ 5 mL dH2O was added to each vial
The triple receptor activation produces even more aggressive appetite suppression, which correlates with more pronounced gastric emptying delays
(In the past, Siegel received research funds from Vivus, which makes Qsymia, a weight-loss medication that is not a GLP-1 agonist.) GLP-1 agonist medications cause the pancreas to release insulin, which helps control blood sugar, and they slow your gastrointestinal tract down, making you feel full longer and reducing hunger, he explains
Standard titration schedule from trials 12-week escalation protocol: Weeks 1-4: 0.6mg weekly Initiation dose Body adapts to amylin effects Minimal side effects at this level Weight loss begins (modest) Weeks 5-8: 1.2mg weekly First dose increase (doubling) Gastric slowing becomes more noticeable Appetite suppression strengthens Accelerated weight loss Weeks 9-12: 1.8mg weekly Second increase Strong satiety effects More pronounced GI effects possible Approaching maximum efficacy Week 13+: 2.4mg weekly (maintenance) Target therapeutic dose Maximum weight loss velocity Maintained indefinitely Nausea typically resolved by this point (adapted) Why this schedule works: Gradual exposure reduces side effects 4-week intervals allow full adaptation Doubling steps (0.61.22.4) are tolerable Proven in hundreds of patients Balances speed with tolerability Use our peptide calculator and peptide dosing guide at SeekPeptides for precise calculations
